Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/11/2010

NASHVILLE, Tenn., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced financial results for the third quarter ending September 30, 2010, increasing revenue guidance for 2010.

Net Revenue:  For the three months ended September 30, 2010, net revenue was $12.2 million, compared with $13.6 million for the same period in 2009. Excluding initial wholesaler stocking of $3.2 million for Caldolor in 2009, net product revenues were up 19% year over year.  Net revenue for the nine months ended September 30, 2010, was $33.1 million, up from $32.8 million for the corresponding prior year period.

Operating Expenses:  Total operating expenses for the three months ended September 30, 2010, decreased 13% to $9.7 million, compared to $11.2 million for the same period in 2009. This decrease was primarily due to significant initial launch costs related to Caldolor in 2009, as well as changes in the Company's product mix that reduced cost of products sold. The decrease in operating expenses coupled with strong revenue performance during the third quarter of 2010 resulted in an increase in operating income over the prior year to $2.4 million.

Operating expenses for the nine-month period ended September 30, 2010, were $28.8 million compared with $27.7 million for the same period in 2009. The difference was primarily due to increased selling and marketing expense from expansion of the Company's hospital sales force in the third quarter of 2009, resulting in operating income of $4.3 million for the nine-month period ended September 30, 2010.

Net Income:  Net income for the three months ended September 30, 2010, was $1.0 million, or $0.05 per diluted share, compared with $1.3 millio
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
3. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
4. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
7. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
8. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
9. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
10. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... personalized immune therapies for operable and inoperable solid tumor cancers, ... at the 7 th Annual Phacilitate Immunotherapy Forum in ... presentation at Phacilitate will take place on January 26 at ...
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... YORK , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ... board of directors of Advaxis, Inc. ("Advaxis" or the ... board has breached its fiduciary duties to shareholders. ... on an investing website reporting that Advaxis had misrepresented ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... 7, 2007 - REGENERX,BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com ... the 2007 Association for Research in,Vision and ... May 9th to discuss TB4's ability to ... process closely,associated with inflammation that, if not ...
... TSX-V: PGA, VANCOUVER, May 07, 2007 /PRNewswire-FirstCall/ - ... results from its Phase I/II study of PAC-113, ... and active,in the treatment of oral Candida infection ... of care. Based on these results,the Company plans ...
Cached Medicine Technology:Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 2Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5
(Date:1/23/2015)... January 23, 2015 Hastings and Hastings, a ... reports a record number of legal representation client review requests ... has been a steady rise in the number of slip ... at home throughout the Valley. With that said, a large ... reviewed by an experienced law firm. Hastings and Hastings is ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... measurement devices implanted inside a living body. The object ... the presence of the implant. An example of a ... long since become standard treatment for heart patients. Researcher ... (TUT) believes that the next tech-savvy generation represents a ...
... conservative treatment may be warranted, study finds , MONDAY, May ... to extend the life of elderly people with kidney cancer ... it suggests, people with such cancer should undergo more conservative ... , Kidney cancer cases have increased over the past 10 ...
... ... 10 SSDI recipients would have found it useful to know representation options before filing ... ... Security disability benefits on their own, only to have their application denied, according to ...
... ... soulful jazz & R&B vocal stylings through his jazz community. , , ... Oakland, CA (PRWEB) May 10, 2010 -- Nicolas ... of Bobby McFerrin,s renowned vocal ensemble " Voicestra" and it,s offshoot, the vocal sextet ...
... ... at Increased Risk for Eye Disease , ... San Francisco, CA (Vocus) May 10, 2010 -- EyeCare America ... this national campaign, in partnership with the National Eye Institute. New research from the Los ...
... The ... state and local reporters assistance in analyzing how the new health reform law will ... great clearinghouse of information about health care issues for children and families." , ... Washington, D.C. (PRWEB) May ...
Cached Medicine News:Health News:Vital functions monitored with wearable and implantable devices 2Health News:Vital functions monitored with wearable and implantable devices 3Health News:Getting Help with Initial Social Security Disability Application Can Speed Access to Benefits 2Health News:Getting Help with Initial Social Security Disability Application Can Speed Access to Benefits 3Health News:Getting Help with Initial Social Security Disability Application Can Speed Access to Benefits 4Health News:Vocalist Nicolas Bearde Unveils his Music Catalogue Through The Jazz Network Worldwide 2Health News:Vocalist Nicolas Bearde Unveils his Music Catalogue Through The Jazz Network Worldwide 3Health News:EyeCare America Partners with the National Eye Institute during May's Healthy Vision Month 2Health News:EyeCare America Partners with the National Eye Institute during May's Healthy Vision Month 3Health News:Georgetown Research Center Helps Reporters Decipher Health Reform Law & Impact on State Residents 2
... The Physique leads are small profile endocardial ... helix. With a lead body size of ... size of 7 F, the Physique lead ... available today. Available in both straight and ...
Used with Temporary Myocardial Heartwires....
Used with permanent pacing leads....
Suture sleeve for permanent pacing leads....
Medicine Products: